about
Do Attachment Style and Emotion Regulation Strategies Indicate Distress in Predictive Testing?Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samplesReducing patients' suicide ideation through training mental health teams in the application of the Dutch multidisciplinary practice guideline on assessment and treatment of suicidal behavior: study protocol of a randomized controlled trial.Anxiety in Huntington's Disease.Suicidal ideation and subsequent completed suicide in both psychiatric and non-psychiatric populations: a meta-analysis.Correlates of sleep disturbances in depressed older persons: the Netherlands study of depression in older persons (NESDO).Training mental health professionals in suicide practice guideline adherence: Cost-effectiveness analysis alongside a randomized controlled trial.Comparing Methods to Denote Treatment Outcome in Clinical Research and Benchmarking Mental Health Care.Improving the application of a practice guideline for the assessment and treatment of suicidal behavior by training the full staff of psychiatric departments via an e-learning supported Train-the-Trainer program: study protocol for a randomized contFactor analysis of behavioural symptoms in Huntington's disease.Discriminant analysis of Beck Depression Inventory and Hamilton Rating Scale for Depression in Huntington's disease.Offspring of a parent with genetic disease: childhood experiences and adult psychological characteristics.Incidence, course, and predictors of apathy in Huntington's disease: a two-year prospective study.Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.[Reaction on 'Psychiatric problems in a motor disorder: psychosis in Huntington's disease'].Screening for cognitive dysfunction in Huntington's disease with the clock drawing test.Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease.Hypothalamic-pituitary-adrenal axis functioning in Huntington's disease and its association with depressive symptoms and suicidality.Medical treatment of behavioral manifestations of Huntington disease.Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers.Subjective insomnia symptoms and sleep duration are not related to hypothalamic-pituitary-adrenal axis activity in older adults.Disease stage and plasma levels of cytokines in Huntington's disease: A 2-year follow-up study.Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].Evaluation of benefit to patients of training mental health professionals in suicide guidelines: cluster randomised trial.The effect of an e-learning supported Train-the-Trainer programme on implementation of suicide guidelines in mental health care.Treatment results for severe psychiatric illness: which method is best suited to denote the outcome of mental health care?Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep DisordersSmartphone-based safety planning and self-monitoring for suicidal patients: Rationale and study protocol of the CASPAR (Continuous Assessment for Suicide Prevention And Research) studyHuntington's Disease Gene Expansion Carriers Are Aware of Their Degree of Apathy[Delayed diagnosis of Huntington's disease in a psychiatric setting]
P50
Q36042915-93306429-1A21-4023-AD22-96B131944876Q36316344-381AA986-9F34-44F0-8AB0-F74B3B98F2B9Q37131903-75F26149-73DE-4E9C-B590-87E46363C1D9Q37304915-601769D7-5B0F-4421-845B-00BDC3A2A543Q38388930-CD4930C6-A360-405E-90E4-5587673AD756Q39091505-EC337A18-CCFD-410B-AF86-D2CF7DDFB424Q39202333-781D5115-FC44-4487-94C2-8ED972D85833Q40654170-617D05E4-9387-4F82-BAD3-376072EF2E81Q41109866-41932763-88B0-429F-83A2-1C4831220171Q42071127-5B17D76F-1085-4364-AD11-7BF8AFA5A2A8Q43972641-3A7AB880-801B-4A73-A036-BD05179D40BFQ44116956-00BEAEC6-8AB6-4D7E-B6D1-74E307D21E2FQ44208991-4515C230-1E7E-43FA-AB29-25EF492B2C54Q44624291-2BF0D6C0-AA86-4A69-86AE-A25A8680E8D0Q45288784-B98FF432-47ED-4413-BEC1-41CB39BB88B4Q45290230-A612EE0C-69A6-4D46-964B-1C0386430C72Q45292572-C12210AB-AFB0-4B65-A287-3B24EFE593EEQ45298853-87A3755E-6B88-4620-B119-44CE6A2E2189Q45299893-60FAF4E1-5E56-40D7-A160-7197F6D06D28Q45303547-BECB130E-470E-4BC4-A7AE-91C773D12FFEQ45304423-4B3F6F7D-11D1-45B6-8638-4C6A921A2B55Q47563064-FAF82D1A-E220-498F-8D69-9905F2EE9546Q47692643-EE6614ED-6606-4534-8515-1C41FFDCD9BCQ47710037-584CD1B9-50BD-4255-9E9D-DED028A18849Q47951803-30164067-09C7-4DA4-91CB-B03D871D8871Q48068418-A832CC5A-6886-48C2-92C0-27772336F767Q48115898-3D451771-C5A1-44CE-B4D9-59C6A79CE1A4Q55669852-B4D3DBC0-600C-46D3-AC7E-D1D56B480CF7Q56968577-825D04DC-AB8C-4179-A774-D886DB192AA2Q62018039-5CF71420-9710-4F31-947B-A892F1F5ED1AQ88907976-46C47B64-7B96-4EC0-A37C-5137DFDBCC81Q95532179-E4C90BC8-0319-48AF-B441-0F307BF43BAA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Erik van Duijn
@en
Erik van Duijn
@nl
type
label
Erik van Duijn
@en
Erik van Duijn
@nl
prefLabel
Erik van Duijn
@en
Erik van Duijn
@nl
P31
P496
0000-0003-2469-6252